{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'For safety, the treatment code will be unblinded by the Sponsor for reporting to the Health', 'Authority of any SUSAR and reasonably associated with the use of the IMP according to either', 'the judgment of the Investigator and/or the Sponsor.', 'In case of a SUSAR, Sanofi Global Pharmacovigilance and Epidemiology will utilize XGRID to', 'reveal medication assignment for regulatory reporting requirements for the particular case.', 'The Sponsor will report all safety observations made during the conduct of the trial in the clinical', 'study report.', '10.6 SAFETY INSTRUCTIONS', '10.6.1 Hypersensitivity', 'Allergic reaction is a potential risk associated with the administration of most therapeutic', 'monoclonal antibodies.', 'Allergic reactions may be defined as allergic reaction-mediated signs and symptoms experienced', 'by patients during or shortly after the pharmacologic or biologic agent given. These reactions may', 'present in a variety of ways, including dizziness, headache, anxiety, dyspnea, hypotension,', 'tachycardia, pruritus, rash, urticaria/angioedema, flushing, nausea, or vomiting. Anaphylaxis may', 'represent the most severe form of infusion reaction, but these events may also occur via non-IgE', 'mediated mechanisms (eg, anaphylactoid reactions), or may occur via other immune-mediated', 'mechanisms (eg, cytokine-mediated). Refer to Appendix L \"Definition of Anaphylaxis\", which', 'describes the clinical criteria for the diagnosis of anaphylaxis.', 'Patients must be monitored for at least 30 minutes after each study-site administered', 'investigational product administration for any signs or symptoms of a hypersensitivity reaction.', 'Trained personnel and medications should be available to treat anaphylaxis or any severe allergic', 'reaction if it occurs. Furthermore, the patients will be advised, when the IMP is administered at', 'home, to self-monitor for potential signs and symptoms that may suggest a hypersensitive reaction', 'for at least 30 minutes after administration.', 'Anaphylactic reactions or, systemic allergic reactions that are related to IMP and require treatment', 'must be reported as an AESI (within 24 hours, for further details, see AESI definition in', 'Section 10.4.1.3 and Appendix L) and study medication should be permanently discontinued.', 'Anti-drug antibodies and PK samples will be collected near the onset and resolution of the AESI', 'for any additional analysis.', '10.6.2 Severe Injection Site Reactions', 'Based on the SC mode of administration of high doses of protein and on a higher incidence of', 'local injection site reactions observed at the highest IMP dose level evaluated in adults', '(300 mg weekly dose), severe injection site reactions, are considered as a potential risk. Patients', 'who experience an injection site reaction must be closely monitored for the possibility of a more', 'intense injection site reaction with a future injection. Any severe injection reaction that lasts over', 'Property of the Sanofi Group - strictly confidential', 'Page 106', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '24 hours will be reported as an AESI with immediate notification. IMP must be temporarily', 'interrupted until the clinical study director (CSD) has evaluated the case. ADA and PK samples', 'will be collected near the onset and resolution of the AESI for any additional analysis.', 'Prophylactic reatment/premedication for an injection site reaction is not permitted.', '10.6.3 Infections', 'Some biologic therapies have been associated with an increased risk of infection, including', 'opportunistic infections. As a precautionary measure, the Investigator is required to carefully', 'monitor for any signs or symptoms of infection such as, but not limited to, increased body', 'temperature, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates, or serious febrile', 'systemic illness.', 'A complete diagnostic work-up should be performed (ie, cultures for fungi and/or mycobacteria', 'other than tuberculosis, histopathological or cytological evaluation, antigen detection and serum', 'antibody titers). Patients should be referred to an infectious disease specialist if deemed necessary', 'for diagnostic work up and appropriate treatment.', 'Infections or infestations that do not respond to medical treatment should have study drug', 'discontinued until the infection is resolved.', 'For any opportunistic infection, such as TB or other infections whose nature or course may', 'suggest an immunocompromised status (See Section 10.3.2) patients must be permanently', 'discontinued from study medication.', 'Infections as defined in Section 10.4.1.3 should be reported as AESIs within 24 hours.', 'Since dupilumab binds to IL-4Ra, preventing IL-4 and IL-13 activation of their respective', 'receptors, it inhibits the T-helper 2 (Th2) cytokines production. Infections with a diversity of', 'helminthic parasites elicit eosinophilia via stimulation of Th2-like lymphocyte responses. The Th2', 'response is characterized by production of IL-4, IL-13 and IL-5, subsequently generating IgG1', 'and IgE-secreting cells, and eliciting eosinophilia. Eosinophilia is prominent in a number of', 'helminthic parasitic diseases. The eosinophilic response to helminths is determined both by the', \"host's immune response and by the parasite, including its distribution, migration, and development\", 'within the infected host. Therefore, patients treated with dupilumab may potentially have an', 'increased risk of parasitic infection.', 'In order to minimize this risk, any patient with an active parasitic infection should be excluded', 'from the study (see Section 7.2.3). Similarly, patients with suspected parasitic infection, or those', 'at high risk of parasitic infection are also excluded, unless clinical and (if necessary) laboratory', 'assessments have ruled out active infection before randomization. During the study, appearance of', 'signs or symptoms (such as abdominal pain, cough, diarrhea, fever, fatigue hepatosplenomegaly)', 'that could be associated with a parasitic infection should be carefully evaluated, especially if there', 'is a history of parasitic exposure through recent travel to/or residence in endemic areas, especially', 'when conditions are conducive to infection (eg, extended stay, rural or heavily populated informal', 'settlements, lack of running water, consumption of uncooked, undercooked, or otherwise', 'Property of the Sanofi Group - strictly confidential', 'Page 107', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}